Ideaya Total Liab vs Common Stock Analysis

IDYA Stock

USD 26.79 0.19 0.71%

Ideaya Biosciences financial indicator trend analysis is infinitely more than just investigating Ideaya Biosciences recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Ideaya Biosciences is a good investment. Please check the relationship between Ideaya Biosciences Total Liab and its Common Stock accounts. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Ideaya Biosciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in manufacturing.

For information on how to trade Ideaya Stock refer to our How to Trade Ideaya Stock guide.

Total Liab vs Common Stock

Total Liab vs Common Stock Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Ideaya Biosciences Total Liab account and Common Stock. At this time, the significance of the direction appears to have fragmental relationship.

The correlation between Ideaya Biosciences' Total Liab and Common Stock is 0.46. Overlapping area represents the amount of variation of Total Liab that can explain the historical movement of Common Stock in the same time period over historical financial statements of Ideaya Biosciences, assuming nothing else is changed. The correlation between historical values of Ideaya Biosciences' Total Liab and Common Stock is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Total Liab of Ideaya Biosciences are associated (or correlated) with its Common Stock. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Common Stock has no effect on the direction of Total Liab i.e., Ideaya Biosciences' Total Liab and Common Stock go up and down completely randomly.

Correlation Coefficient

0.46

Relationship Direction	Positive
Relationship Strength	Weak

View All Relationships

Total Liab

The total amount of all liabilities that a company has, including both short-term and long-term liabilities.

Common Stock

Most indicators from Ideaya Biosciences' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Ideaya Biosciences current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Ideaya Biosciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in manufacturing.

For information on how to trade Ideaya Stock refer to our How to Trade Ideaya Stock guide.The current year's Enterprise Value is expected to grow to about 2 B, whereas Selling General Administrative is forecasted to decline to about 16.4 M.

	2021	2022	2023	2024 (projected)
Interest Income	506K	3.8M	21.5M	22.5M
Net Interest Income	506K	3.8M	21.5M	22.5M

Interest Income Net Interest Income

Ideaya Biosciences fundamental ratios Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Other Liab	Net Tangible Assets	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Other Assets	Cash And Short Term Investments	Common Stock Shares Outstanding	Short Term Investments	Long Term Debt Total	Non Current Liabilities Total	Capital Surpluse	Other Current Assets	Other Stockholder Equity	Total Liab	Net Invested Capital	Property Plant And Equipment Gross	Total Current Assets
Total Assets		0.79	0.79	0.99	0.34	0.97	0.77	-0.99	-0.99	0.94	0.99	0.86	0.3	0.13	0.91	0.9	0.89	-0.78	-0.33	0.98	0.89	0.99	0.34	0.99	0.84	0.99
Other Current Liab	0.79		0.82	0.77	0.3	0.86	0.67	-0.74	-0.82	0.74	0.73	0.65	0.08	0.18	0.89	0.88	0.88	-0.34	-0.26	0.86	0.82	0.8	0.68	0.77	0.89	0.8
Total Current Liabilities	0.79	0.82		0.74	0.75	0.85	0.83	-0.76	-0.75	0.56	0.76	0.69	0.09	0.19	0.89	0.77	0.82	-0.3	-0.14	0.84	0.94	0.74	0.79	0.74	0.72	0.78
Total Stockholder Equity	0.99	0.77	0.74		0.26	0.97	0.75	-0.98	-0.99	0.95	0.98	0.86	0.29	0.0	0.89	0.9	0.87	-0.81	-0.46	0.98	0.86	1.0	0.27	1.0	0.84	0.98
Other Liab	0.34	0.3	0.75	0.26		0.38	0.54	-0.34	-0.25	0.02	0.34	0.25	-0.17	0.1	0.47	0.26	0.41	0.05	0.18	0.35	0.62	0.26	0.65	0.26	0.12	0.34
Net Tangible Assets	0.97	0.86	0.85	0.97	0.38		0.84	-0.95	-0.97	0.88	0.95	0.82	0.26	0.01	0.93	0.92	0.91	-0.67	-0.45	1.0	0.93	0.97	0.48	0.97	0.89	0.96
Property Plant And Equipment Net	0.77	0.67	0.83	0.75	0.54	0.84		-0.75	-0.78	0.58	0.76	0.58	0.53	0.1	0.83	0.73	0.8	-0.37	-0.23	0.84	0.89	0.72	0.65	0.75	0.76	0.79
Net Debt	-0.99	-0.74	-0.76	-0.98	-0.34	-0.95	-0.75		0.98	-0.93	-1.0	-0.89	-0.33	-0.12	-0.9	-0.9	-0.87	0.8	0.33	-0.95	-0.88	-0.98	-0.27	-0.98	-0.82	-0.98
Retained Earnings	-0.99	-0.82	-0.75	-0.99	-0.25	-0.97	-0.78	0.98		-0.95	-0.98	-0.83	-0.36	-0.09	-0.92	-0.93	-0.91	0.76	0.38	-0.98	-0.88	-0.99	-0.33	-0.99	-0.89	-0.99
Accounts Payable	0.94	0.74	0.56	0.95	0.02	0.88	0.58	-0.93	-0.95		0.92	0.78	0.27	0.09	0.8	0.85	0.82	-0.86	-0.38	0.9	0.71	0.96	0.12	0.95	0.8	0.94
Cash	0.99	0.73	0.76	0.98	0.34	0.95	0.76	-1.0	-0.98	0.92		0.89	0.33	0.11	0.89	0.87	0.86	-0.81	-0.34	0.96	0.87	0.98	0.27	0.98	0.8	0.98
Non Current Assets Total	0.86	0.65	0.69	0.86	0.25	0.82	0.58	-0.89	-0.83	0.78	0.89		0.3	0.19	0.77	0.77	0.64	-0.71	-0.33	0.82	0.74	0.85	0.22	0.86	0.75	0.79
Non Currrent Assets Other	0.3	0.08	0.09	0.29	-0.17	0.26	0.53	-0.33	-0.36	0.27	0.33	0.3		0.26	0.3	0.32	0.28	-0.22	-0.01	0.29	0.29	0.25	0.02	0.29	0.47	0.28
Other Assets	0.13	0.18	0.19	0.0	0.1	0.01	0.1	-0.12	-0.09	0.09	0.11	0.19	0.26		0.16	0.03	0.11	0.0	0.81	0.05	0.08	0.04	0.33	0.0	0.11	0.11
Cash And Short Term Investments	0.91	0.89	0.89	0.89	0.47	0.93	0.83	-0.9	-0.92	0.8	0.89	0.77	0.3	0.16		0.97	0.97	-0.48	-0.25	0.94	0.97	0.89	0.57	0.89	0.9	0.91
Common Stock Shares Outstanding	0.9	0.88	0.77	0.9	0.26	0.92	0.73	-0.9	-0.93	0.85	0.87	0.77	0.32	0.03	0.97		0.95	-0.53	-0.4	0.92	0.91	0.9	0.41	0.9	0.94	0.9
Short Term Investments	0.89	0.88	0.82	0.87	0.41	0.91	0.8	-0.87	-0.91	0.82	0.86	0.64	0.28	0.11	0.97	0.95		-0.48	-0.24	0.91	0.94	0.88	0.52	0.87	0.87	0.92
Long Term Debt Total	-0.78	-0.34	-0.3	-0.81	0.05	-0.67	-0.37	0.8	0.76	-0.86	-0.81	-0.71	-0.22	0.0	-0.48	-0.53	-0.48		0.36	-0.69	-0.44	-0.81	0.24	-0.81	-0.45	-0.77
Non Current Liabilities Total	-0.33	-0.26	-0.14	-0.46	0.18	-0.45	-0.23	0.33	0.38	-0.38	-0.34	-0.33	-0.01	0.81	-0.25	-0.4	-0.24	0.36		-0.42	-0.27	-0.42	0.14	-0.46	-0.41	-0.32
Capital Surpluse	0.98	0.86	0.84	0.98	0.35	1.0	0.84	-0.95	-0.98	0.9	0.96	0.82	0.29	0.05	0.94	0.92	0.91	-0.69	-0.42		0.92	0.97	0.46	0.98	0.9	0.97
Other Current Assets	0.89	0.82	0.94	0.86	0.62	0.93	0.89	-0.88	-0.88	0.71	0.87	0.74	0.29	0.08	0.97	0.91	0.94	-0.44	-0.27	0.92		0.85	0.62	0.86	0.83	0.89
Other Stockholder Equity	0.99	0.8	0.74	1.0	0.26	0.97	0.72	-0.98	-0.99	0.96	0.98	0.85	0.25	0.04	0.89	0.9	0.88	-0.81	-0.42	0.97	0.85		0.28	1.0	0.84	0.99
Total Liab	0.34	0.68	0.79	0.27	0.65	0.48	0.65	-0.27	-0.33	0.12	0.27	0.22	0.02	0.33	0.57	0.41	0.52	0.24	0.14	0.46	0.62	0.28		0.27	0.49	0.36
Net Invested Capital	0.99	0.77	0.74	1.0	0.26	0.97	0.75	-0.98	-0.99	0.95	0.98	0.86	0.29	0.0	0.89	0.9	0.87	-0.81	-0.46	0.98	0.86	1.0	0.27		0.84	0.98
Property Plant And Equipment Gross	0.84	0.89	0.72	0.84	0.12	0.89	0.76	-0.82	-0.89	0.8	0.8	0.75	0.47	0.11	0.9	0.94	0.87	-0.45	-0.41	0.9	0.83	0.84	0.49	0.84		0.82
Total Current Assets	0.99	0.8	0.78	0.98	0.34	0.96	0.79	-0.98	-0.99	0.94	0.98	0.79	0.28	0.11	0.91	0.9	0.92	-0.77	-0.32	0.97	0.89	0.99	0.36	0.98	0.82

Click cells to compare fundamentals

Ideaya Biosciences Account Relationship Matchups

Ideaya Biosciences fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	113.0M	298.3M	381.3M	388.0M	649.3M	681.8M
Other Current Liab	63K	7.0M	17.3M	25.0M	17.0M	11.3M
Total Current Liabilities	6.9M	38.6M	45.2M	31.7M	27.1M	24.7M
Total Stockholder Equity	100.4M	198.3M	301.5M	349.5M	621.1M	652.1M
Other Liab	34K	56.2M	31.2M	5.2M	6.0M	5.7M
Net Tangible Assets	100.4M	198.3M	301.5M	349.5M	401.9M	422.0M
Property Plant And Equipment Net	9.7M	9.5M	8.7M	9.0M	8.4M	8.5M
Net Debt	(27.3M)	(65.3M)	(86.9M)	(65.2M)	(154.1M)	(146.4M)
Retained Earnings	(92.5M)	(127.0M)	(176.7M)	(235.4M)	(348.4M)	(330.9M)
Accounts Payable	709K	953K	2.1M	4.3M	6.6M	6.9M
Cash	34.1M	72.0M	92.0M	68.6M	157.0M	164.9M
Non Current Assets Total	12.5M	9.7M	130.4M	17.5M	116.7M	122.5M
Non Currrent Assets Other	1.3M	82K	397K	205K	782K	416.2K
Other Assets	122K	188K	397K	205K	184.5K	239.2K
Cash And Short Term Investments	100.5M	283.6M	368.1M	373.1M	525.1M	275.6M
Common Stock Total Equity	2K	3K	4K	5K	5.8K	6.0K
Common Stock Shares Outstanding	20.2M	24.7M	35.3M	41.4M	57.5M	32.6M
Short Term Investments	64.9M	211.5M	154.7M	296.2M	368.1M	184.2M
Liabilities And Stockholders Equity	113.0M	298.3M	381.3M	388.0M	649.3M	681.8M
Non Current Liabilities Total	5.7M	61.4M	34.7M	6.8M	1.1M	1.1M
Capital Surpluse	192.8M	325.3M	479.0M	587.7M	675.9M	709.7M
Capital Lease Obligations	6.8M	6.7M	5.2M	3.5M	2.9M	3.9M
Other Current Assets	2.7M	6.3M	6.2M	5.4M	7.5M	4.6M
Other Stockholder Equity	79.8M	325.3M	479.0M	587.7M	968.9M	1.0B
Total Liab	113.0M	298.3M	381.3M	388.0M	28.2M	26.8M
Net Invested Capital	100.4M	198.3M	301.5M	349.5M	621.1M	652.1M
Property Plant And Equipment Gross	9.7M	4.3M	14.3M	16.5M	18.0M	11.3M
Total Current Assets	100.5M	288.6M	251.0M	370.5M	532.6M	559.3M
Accumulated Other Comprehensive Income	65K	7K	(712K)	(2.9M)	562K	590.1K
Non Current Liabilities Other	34K	12K	34.7M	6.8M	7.8M	7.7M
Net Working Capital	94.7M	250.0M	205.8M	338.7M	505.5M	530.8M
Short Term Debt	1.1M	3.1M	3.4M	3.7M	3.5M	2.3M
Common Stock	2K	3K	4K	5K	7K	3.6K
Property Plant Equipment	9.7M	9.5M	4.8M	6.5M	7.5M	7.2M
Capital Stock	2K	3K	4K	5K	7K	3.9K

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

RSI	Rush Street Interactive
OKTA	Okta Inc
BAC	Bank of America

When determining whether Ideaya Biosciences offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Ideaya Biosciences' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Ideaya Biosciences Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Ideaya Biosciences Stock:

How To Invest In Ideaya

Details

Is Ideaya Stock a good investment?

Details

What is Ideaya Biosciences' Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Ideaya Biosciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in manufacturing.

For information on how to trade Ideaya Stock refer to our How to Trade Ideaya Stock guide.

You can also try the Price Exposure Probability module to analyze equity upside and downside potential for a given time horizon across multiple markets.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Ideaya Biosciences. If investors know Ideaya will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Ideaya Biosciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(2.33)

Revenue Per Share

0.051

Quarterly Revenue Growth

(0.03)

Return On Assets

(0.16)

Return On Equity

(0.21)

The market value of Ideaya Biosciences is measured differently than its book value, which is the value of Ideaya that is recorded on the company's balance sheet. Investors also form their own opinion of Ideaya Biosciences' value that differs from its market value or its book value, called intrinsic value, which is Ideaya Biosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Ideaya Biosciences' market value can be influenced by many factors that don't directly affect Ideaya Biosciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Ideaya Biosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Ideaya Biosciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Ideaya Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Ideaya Total Liab vs Common Stock Analysis

Total Liab vs Common Stock

Total Liab vs Common Stock Correlation Analysis

Correlation Coefficient

Total Liab

Common Stock

Ideaya Biosciences fundamental ratios Correlations

Ideaya Biosciences Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Ideaya Biosciences fundamental ratios Accounts

Also Currently Popular

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Other Stockholder Equity	+ 1.0	Total Stockholder Equity
Net Invested Capital	+ 1.0	Total Stockholder Equity
Capital Surpluse	+ 1.0	Net Tangible Assets
Net Invested Capital	+ 1.0	Other Stockholder Equity
Total Stockholder Equity	+ 0.99	Total Assets
Cash	+ 0.99	Total Assets

Cash	- 1.0	Net Debt
Total Current Assets	- 0.99	Retained Earnings
Net Invested Capital	- 0.99	Retained Earnings
Other Stockholder Equity	- 0.99	Retained Earnings
Retained Earnings	- 0.99	Total Stockholder Equity
Retained Earnings	- 0.99	Total Assets